ResApp Health Limited announced that its Indian COVID-19 clinical study has completed recruitment of over 100 COVID-19 positive patients ahead of time. Given the fast recruitment and the value of additional data, the study has been expanded to 200 positive cases and is expected to complete recruitment by the end of November 2021. ResApp's Indian clinical trial partner, Triomics, is now recruiting participants at all three hospital sites in India. The increase in case numbers will provide for greater robustness and certainty in evaluating COVID-19 screening test algorithm candidates to give ResApp the highest chance of developing a truly accurate algorithm for COVID-19 screening. ResApp is also recruiting patients in two US clinical studies with enrolment now expected to complete in mid-December. The combination of data from India and the US will be crucial to testing the robustness of the algorithms across population groups.